Author Archives: Michael Gilman

This blog was written by Mike Gilman, CEO of Obsidian Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC. Consider the leech – the first living medicine. In its heyday in the 19th century –

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I stumbled into a bit of a mess a few weeks ago. It was with the best of intentions, of course.

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. We all have stuff lying around our homes or offices that we have no further use for but that might be

This blog was written by Mike Gilman, CEO of Padlock Therapeutics and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Padlock Therapeutics is my second startup, and it’s not nearly as scary as the first one. Not

This blog was written by Mike Gilman, Atlas’ EIR and CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I thought I was done with immunology. I’m not formally trained as an immunologist, but I fell for it hard

In my last post, I argued that the key to the success – and perhaps even the survival – of the biopharma industry is to excel at risk management. We are in an inherently risky business, where there are thousands of

Humans are supremely lousy at evaluating risk. We get nervous when we fly but not when we drive. We worry about terrorist attacks when we’re far more likely to die in our own bathrooms. We flock to buy tickets for